Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Satsuma Pharmaceuticals Inc | STSA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.10 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.10 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.01 - 1.14 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.10 | USD |
Satsuma Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 36.47M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Satsuma Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/15/2023 | 07:00 | GlobeNewswire Inc. | Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STSA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 1.06 | 1.14 | 1.01 | 1.07 | 652,702 | 0.04 | 3.77% |
| 3 Years | 5.14 | 8.08 | 0.59 | 2.14 | 326,495 | -4.04 | -78.60% |
| 5 Years | 19.00 | 36.105 | 0.59 | 4.67 | 410,364 | -17.90 | -94.21% |
Satsuma Pharmaceuticals Description
| Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device. |
